Fate Therapeutics Inc (FATE)
3.27
0.00 (0.00%)
USD |
NASDAQ |
Jun 28, 16:00
3.27
0.00 (0.00%)
After-Hours: 20:00
Fate Therapeutics Research and Development Expense (TTM): 139.10M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 139.10M |
| December 31, 2023 | 172.60M |
| September 30, 2023 | 227.97M |
| June 30, 2023 | 273.51M |
| March 31, 2023 | 313.94M |
| December 31, 2022 | 320.45M |
| September 30, 2022 | 302.78M |
| June 30, 2022 | 276.09M |
| March 31, 2022 | 242.81M |
| December 31, 2021 | 215.52M |
| September 30, 2021 | 184.99M |
| June 30, 2021 | 162.55M |
| March 31, 2021 | 141.20M |
| December 31, 2020 | 125.62M |
| September 30, 2020 | 111.85M |
| June 30, 2020 | 104.36M |
| March 31, 2020 | 99.32M |
| December 31, 2019 | 87.77M |
| September 30, 2019 | 76.66M |
| June 30, 2019 | 67.09M |
| March 31, 2019 | 62.28M |
| December 31, 2018 | 56.02M |
| Date | Value |
|---|---|
| September 30, 2018 | 51.82M |
| June 30, 2018 | 46.76M |
| March 31, 2018 | 37.87M |
| December 31, 2017 | 34.36M |
| September 30, 2017 | 30.70M |
| June 30, 2017 | 28.93M |
| March 31, 2017 | 27.78M |
| December 31, 2016 | 26.45M |
| September 30, 2016 | 25.66M |
| June 30, 2016 | 23.85M |
| March 31, 2016 | 21.93M |
| December 31, 2015 | 19.86M |
| September 30, 2015 | 18.29M |
| June 30, 2015 | 17.37M |
| March 31, 2015 | 16.48M |
| December 31, 2014 | 16.44M |
| September 30, 2014 | 15.60M |
| June 30, 2014 | 14.90M |
| March 31, 2014 | 14.00M |
| December 31, 2013 | 12.01M |
| September 30, 2013 | 12.38M |
| June 30, 2013 | 12.32M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
67.09M
Minimum
Jun 2019
320.45M
Maximum
Dec 2022
182.31M
Average
167.57M
Median
Research and Development Expense (TTM) Benchmarks
| Amicus Therapeutics Inc | 139.21M |
| Ocular Therapeutix Inc | 67.04M |
| AnaptysBio Inc | 134.37M |
| Stoke Therapeutics Inc | 84.97M |
| Olema Pharmaceuticals inc | 93.20M |